Development of systemic therapy for hepatocellular carcinoma at 2013: Updates and insights

Table 2 List of selected ongoing clinical trials on novel targeted therapy for hepatocellular carcinoma

Drug	Design	Phase	Status	NCT number
Single-agent
TKI
Dovitinib (TKI258)	Dovitinib vs sorafenib (1st line)	Randomized phase II	Compl-eted	NCT01232296
Carbo- zantinib	Carbozantinib vs placebo (2nd line)	Phase III	Ongoing	NCT01908426
c-MET inhibitor
Tivantinib	Tivantinib vs placebo (2nd line)	Phase III	Ongoing	NCT01755767
INC280	INC280 (1st line in c-MET expressing HCC)	Phase I/II	Ongoing	NCT01737827
Oncolytic poxvirus
JX594	JX594 vs placebo (2nd line)	Randomized phase II	Ongoing	NCT01387555
Glypican-3
GC33	GC33 vs placebo (2nd line)	Phase III	Compl-eted	NCT01507168
mTOR inhibitor
Everolimus	Everolimus vs placebo (2nd line)	Phase III	Press release	NCT01035229
Temsir- olimus	Temsirolimus (1st or 2nd line)	Phase II	Abstract	NCT01251458
CC-223	CC-223 in solid tumors including HCC	Phase I/II	Ongoing	NCT01177397
Arginine deprivation therapy
ADI-PEG 20	ADI-PEG 20 vs placebo (2nd line)	Phase III	Ongoing	NCT01287585
Combination
Sorafenib	Sorafenib + doxorubicin vs sorafenib	Phase III	Accrual	NCT01015833
Sorafenib	TACE + sorafenib vs TACE (ECOG 1208)	Phase III	Accrual	NCT01004978
Everolimus	TACE + everolimus vs TACE	Randomized phase II	Accrual	NCT01379521
Axitinib	TACE + axitinib	Phase II	Accrual	NCT01352728
Bevacizumab and Erlotinib	Bevacizumab + erlotinib vs sorafenib	Randomized phase II	Accrual	NCT01180959

TACE: Transarterial chemoembolization; TKI: Tyrosine kinase inhibitor; HCC: Hepatocellular carcinoma; c-MET: c-mesenchymal-epithelial transition factor-1.